

## Supplementary Online Content

Takahashi M, Cortés J, Dent R, et al. Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial. *JAMA Netw Open*. 2023;6(11):e2342107.  
doi:10.1001/jamanetworkopen.2023.42107

**eTable 1.** List of Countries that Enrolled Patients in the Global KEYNOTE-522 Study

**eTable 2.** First EFS Events by Category: Subgroup of Patients Enrolled in Asia

**eFigure.** Overall Survival: Subgroup of Patients Enrolled in Asia

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** List of Countries that Enrolled Patients in the Global KEYNOTE-522 Study

---

<b>Country</b>
Australia
Brazil
Canada
Columbia
France
Germany
Ireland
Israel
Italy
Japan
Poland
Portugal
Russia
Singapore
South Korea
Spain
Sweden
Taiwan
Turkey
United Kingdom
United States of America

---

**eTable 2.** First EFS Events by Category: Subgroup of Patients Enrolled in Asia

<b>Event</b>	<b>Pembrolizumab + Chemotherapy/ Pembrolizumab n = 136</b>	<b>Placebo + Chemotherapy/ Placebo n = 80</b>
Any EFS event	13 (9.6)	20 (25.0)
Distant recurrence	8 (5.9)	15 (18.8)
Local recurrence <sup>a</sup>	1 (0.7)	2 (2.5)
Progression of disease that precludes definitive surgery	1 (0.7)	2 (2.5)
Secondary primary malignancy <sup>b</sup>	2 (1.5)	0
Death	1 (0.7)	1 (1.3)

EFS, event-free survival.


All values are n (%).

<sup>a</sup>One patient in each treatment group had subsequent distant recurrence.

<sup>b</sup>Secondary primary malignancy sites were bone marrow and stomach.

Data cutoff date: March 23, 2021.

eFigure. Overall survival: subgroup of patients enrolled in Asia.



HR, hazard ratio; OS, overall survival.  
Data cutoff date: March 23, 2021.